Welcome to our dedicated page for Okyo Pharma news (Ticker: EMMLF), a resource for investors and traders seeking the latest updates and insights on Okyo Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Okyo Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Okyo Pharma's position in the market.
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) has partnered with Ora, Inc., a prominent ophthalmology CRO, to advance the development of its lead candidate, OK-101, for treating dry eye disease. This innovative drug utilizes Membrane-Anchored-Peptide (MAP) Technology to enhance drug retention on the ocular surface. The partnership aims to navigate regulatory pathways as OK-101 progresses to clinical trials. The increasing prevalence of dry eye conditions highlights the significant market potential for effective therapies, making this collaboration crucial for addressing unmet medical needs.
OKYO Pharma Limited (OTCQB: EMMLF) announced positive preclinical results for OK-201, a non-opioid analgesic drug candidate, in a mouse model for neuropathic corneal pain. The collaboration with Dr. Pedram Hamrah at Tufts Medical Center showed that OK-201 reduced corneal pain response akin to gabapentin, marking it as a potential treatment option. With no current FDA-approved medications for ocular pain, the findings could significantly impact patient care. Additionally, the company is progressing with OK-101, targeting inflammatory pathways for dry eye syndrome, with IND submission expected in 2022.
OKYO (OTCQB: EMMLF) has appointed Dr. Rajkumar Patil as Chief Scientific Officer. With over 30 years in ophthalmic and pharmaceutical R&D, Dr. Patil has held significant roles at industry leaders like Ora Inc. and Alcon/Novartis. His expertise will support the development of OK-101, a novel drug candidate targeting inflammatory dry eye diseases and ocular pain, addressing a significant unmet medical need. CEO Gary S Jacob emphasized the importance of Dr. Patil's experience in driving clinical development at this crucial time for the company.
OKYO Pharma Limited announced the issuance of 250,000 new ordinary shares at a price of 4.5p per share due to the exercise of options. This will raise the company's total share capital to 672,816,302 ordinary shares. Applications for admission of these shares have been submitted to the FCA and the London Stock Exchange, with trading expected to commence at 8:00 a.m. on March 3, 2021. This move is part of OKYO's ongoing efforts in developing treatments for inflammatory dry eye diseases and ocular pain.
OKYO Pharma Limited announced the issuance of patent No. 10,899,796 by the USPTO on January 26, 2021. This patent covers innovative bovine adrenal medulla (BAM) peptides linked to lipids aimed at treating neuropathic pain, ocular pain, inflammation, and dry eye disease. The company believes these peptides could serve as non-opioid analgesics, mitigating opioid side effects. CEO Dr. Gary S. Jacob emphasized the significance of this patent for advancing clinical candidates and highlighted the unique lipid anchor as crucial for efficacy in ocular treatments.